Pharmaceutical Research

, Volume 30, Issue 7, pp 1735–1748 | Cite as

Electrospun Rapamycin-Eluting Polyurethane Fibers for Vascular Grafts

  • Jingjia Han
  • Shady Farah
  • Abraham J. DombEmail author
  • Peter I. LelkesEmail author
Research Paper



To develop rapamycin-eluting electrospun polyurethane (PU) vascular grafts that could effectively suppress local smooth muscle cell (SMC) proliferation.


Rapamycin (RM) was incorporated in PU fibers by blend electrospinning using three distinct blending methods. The drug release profiles and the bioavailability of RM-containing PU fibers in the form of fibrous mats and vascular grafts were evaluated up to 77 days in vitro.


RM-contained PU fibers generated by the three distinct blending methods exhibited significantly different fiber diameters (200–500 nm) and distinct RM release kinetics. Young’s moduli of the electrospun fibrous mats increased with higher RM contents and decreased with larger fiber diameters. For all blending methods, RM release kinetics was characteristic of a Fickian diffusion for at least 77 days in vitro. RM-PU fibers generated via powder blending showed the highest encapsulation efficiency. The RM in grafts made of these fibers remained bioactive and was still able to inhibit smooth muscle cell proliferation after 77 days of continual in vitro release.


Electrospun RM-containing PU fibers can serve as effective drug carriers for the local suppression of SMC proliferation and could be used as RM-eluting scaffolds for vascular grafts.


drug release electrospinning rapamycin restenosis smooth muscle cell 





bovine serum albumin


Dulbecco’s Modified of Eagle’s Medium


fetal bovine serum


1, 1, 3, 3, 3-Hexafluoro-2-Propanol


high performance liquid chromatography


normal saline-isopropyl alcohol solution




phosphate buffered saline




poly(lactic-co-glycolic acid)


percutaneous transluminal coronary angioplasty






smooth muscle cell


segmented polyurethane


tissue culture polystyrene



Jingjia Han and Shady Farah equally contributed to this paper. This work was supported by a translational research grant by HUB (DU/BIOMED-IDR/HUJI) from Drexel University and The Hebrew University of Jerusalem. We thank Dr. Gozde Senel-Ayaz (Drexel BIOMED) for her assistance with SEM and Dr. Wahid Khan (IDR) for his assistance with developing the analytical method used to assess drug release.


  1. 1.
    Liu MW, Roubin GS, King III SB. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003;361:247–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Allaire E, Clowes AW. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg. 1997;63:582–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008.Google Scholar
  5. 5.
    Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006;114:2148–53.Google Scholar
  6. 6.
    Adelman SJ. Sirolimus and its analogs and its effects on vascular diseases. Curr Pharm Des. 2010;16:4002–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang X, Venkatraman SS, Boey FY, Loo JS, Tan LP. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials. 2006;27:5588–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM. Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. Biomaterials. 2006;27:2042–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Khan W, Farah S, Domb AJ. Drug eluting stents: developments and current status. J Control Release. 2012;161:703–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Biondi M, Ungaro F, Quaglia F, Netti PA. Controlled drug delivery in tissue engineering. Adv Drug Deliv Rev. 2008;60:229–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Kowalczyk T, Nowicka A, Elbaum D, Kowalewski TA. Electrospinning of bovine serum albumin. Optimization and the use for production of biosensors. Biomacromolecules. 2008;9:2087–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Montero RB, Vial X, Nguyen DT, Farhand S, Reardon M, Pham SM, et al. bFGF-containing electrospun gelatin scaffolds with controlled nano-architectural features for directed angiogenesis. Acta Biomater. 2012;8:1778–91.Google Scholar
  13. 13.
    Ekaputra AK, Prestwich GD, Cool SM, Hutmacher DW. The three-dimensional vascularization of growth factor-releasing hybrid scaffold of poly (epsilon-caprolactone)/collagen fibers and hyaluronic acid hydrogel. Biomaterials. 2011;32:8108–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Hyung II RM, Kim JS, Konno T, Takai M, Ishihara K. Preparation of electrospun poly(L-lactide-co-caprolactone-co-glycolide)/phospholipid polymer/rapamycin blended fibers for vascular application. Curr Appl Phys. 2009;9:249–51.CrossRefGoogle Scholar
  15. 15.
    Okuda T, Tominaga K, Kidoaki S. Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J Control Release. 2010;143:258–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Xie J, Wang CH. Electrospun micro- and nanofibers for sustained delivery of paclitaxel to treat C6 glioma in vitro. Pharm Res. 2006;23:1817–26.PubMedCrossRefGoogle Scholar
  17. 17.
    Cui W, Li X, Zhu X, Yu G, Zhou S, Weng J. Investigation of drug release and matrix degradation of electrospun poly(DL-lactide) fibers with paracetanol inoculation. Biomacromolecules. 2006;7:1623–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Li M, Guo Y, Wei Y, MacDiarmid AG, Lelkes PI. Electrospinning polyaniline-contained gelatin nanofibers for tissue engineering applications. Biomaterials. 2006;27:2705–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Li M, Mondrinos MJ, Chen X, Gandhi MR, Ko FK, Lelkes PI. Co-electrospun poly(lactide-co-glycolide), gelatin, and elastin blends for tissue engineering scaffolds. J Biomed Mater Res A. 2006;79:963–73.PubMedGoogle Scholar
  20. 20.
    Uttayarat P, Perets A, Li M, Pimton P, Stachelek SJ, Alferiev I, et al. Micropatterning of three-dimensional electrospun polyurethane vascular grafts. Acta Biomater. 2010;6:4229–37.Google Scholar
  21. 21.
    Crapo PM, Wang Y. Physiologic compliance in engineered small-diameter arterial constructs based on an elastomeric substrate. Biomaterials. 2010;31:1626–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Han J, Lazarovici P, Pomerantz C, Chen X, Wei Y, Lelkes PI. Co-electrospun blends of PLGA, gelatin, and elastin as potential nonthrombogenic scaffolds for vascular tissue engineering. Biomacromolecules. 2011;12:399–408.PubMedCrossRefGoogle Scholar
  23. 23.
    Naseerali CP, Hari PR, Sreenivasan K. The release kinetics of drug eluting stents containing sirolimus as coated drug: role of release media. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878:709–12.CrossRefGoogle Scholar
  24. 24.
    Okner R, Oron M, Tal N, Nyska A, Kumar N, Mandler D, et al. Electrocoating of stainless steel coronary stents for extended release of paclitaxel. J Biomed Mater Res A. 2009;88:427–36.Google Scholar
  25. 25.
    Uttayarat P, Chen M, Li M, Allen FD, Composto RJ, Lelkes PI. Microtopography and flow modulate the direction of endothelial cell migration. Am J Physiol Heart Circ Physiol. 2008;294:H1027–1035.PubMedCrossRefGoogle Scholar
  26. 26.
    Mack MJ, Banning AP, Serruys PW, Morice MC, Taeymans Y, Van Nooten G, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg. 2011;92:2140–6.Google Scholar
  27. 27.
    Barner HB. Status of percutaneous coronary intervention and coronary artery bypass. Eur J Cardio-Thorac. 2006;30:419–24.Google Scholar
  28. 28.
    Mo XM, Xu CY, Kotaki M, Ramakrishna S. Electrospun P(LLA-CL) nanofiber: a biomimetic extracellular matrix for smooth muscle cell and endothelial cell proliferation. Biomaterials. 2004;25:1883–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Zong X, Kim K, Fang D, Ran S, Hsiao B, Chu B. Structure and process relationship of electrospun bioabsorbable nanofiber membranes. Polymer. 2002;43:4403–12.CrossRefGoogle Scholar
  30. 30.
    He SW, Li SS, Hu ZM, Yu JR, Chen L, Zhu J. Effects of three parameters on the diameter of electrospun poly(ethylene oxide) nanofibers. J Nanosci Nanotechnol. 2011;11:1052–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Han J, Chen TX, Branford-White CJ, Zhu LM. Electrospun shikonin-loaded PCL/PTMC composite fiber mats with potential biomedical applications. Int J Pharm. 2009;382:215–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Desai K, Kit K, Li J, Zivanovic S. Morphological and surface properties of electrospun chitosan nanofibers. Biomacromolecules. 2008;9:1000–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Gandhi PJ, Murthy ZVP. Solubility and crystal size of sirolimus in different organic solvents. J Chem Eng Data. 2010;55:5050–4.CrossRefGoogle Scholar
  34. 34.
    Tan EP, Ng SY, Lim CT. Tensile testing of a single ultrafine polymeric fiber. Biomaterials. 2005;26:1453–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos. 1998;26:83–4.Google Scholar
  36. 36.
    Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213:25–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Verreck G, Chun I, Rosenblatt J, Peeters J, Dijck AV, Mensch J, et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release. 2003;92:349–60.Google Scholar
  38. 38.
    Yang Y, Li X, Cui W, Zhou S, Tan R, Wang C. Structural stability and release profiles of proteins from core-shell poly (DL-lactide) ultrafine fibers prepared by emulsion electrospinning. J Biomed Mater Res A. 2008;86:374–85.PubMedGoogle Scholar
  39. 39.
    Huatan H, Collett JH, Attwood D, Booth C. Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins. Biomaterials. 1995;16:1297–303.PubMedCrossRefGoogle Scholar
  40. 40.
    Innocente F, Mandracchia D, Pektok E, Nottelet B, Tille JC, de Valence S, et al. Paclitaxel-eluting biodegradable synthetic vascular prostheses: a step toward reduction of neointima formation? Circulation. 2009;120(11 Suppl):S37–45.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.School of Biomedical Engineering, Science and Health SystemsDrexel UniversityPhiladelphiaUSA
  2. 2.School of Pharmacy, Faculty of MedicineThe Hebrew University of JerusalemJerusalemIsrael
  3. 3.School of Pharmacy, Faculty of Medicine Center for Nanosciences and Nanotechnology Grass Center for Drug Design and SynthesisThe Hebrew University of JerusalemJerusalemIsrael
  4. 4.Department of Bioengineering, College of EngineeringTemple UniversityPhiladelphiaUSA

Personalised recommendations